-
公开(公告)号：US11208633B2
公开(公告)日：2021-12-28
申请号：US16704744
申请日：2019-12-05
Applicant: Pfizer Inc.
Inventor： Jason Arnold Lotvin , Annaliesa Sybil Anderson , Robert G. K. Donald , Michael James Flint , Narender Kumar Kalyan , Kathrin Ute Jansen , Maninder K. Sidhu , Justin Keith Moran , Mark Edward Ruppen , Weiqiang Sun
Abstract: In one aspect, the invention relates to an immunogenic composition that includes a mutant Clostridium difficile toxin A and/or a mutant Clostridium difficile toxin B. The mutant toxin may include a glucosyltransferase domain having at least one mutation and a cysteine protease domain having at least one mutation, relative to the corresponding wild-type C. difficile toxin. The mutant toxins may include at least one amino acid that is chemically crosslinked. In another aspect, the invention relates to methods and compositions for use in culturing Clostridium difficile and in producing C. difficile toxins.
-
公开(公告)号：US20210024589A1
公开(公告)日：2021-01-28
申请号：US17060067
申请日：2020-09-30
Applicant: PFIZER INC.
Inventor： Annaliesa Sybil Anderson , Susan Kay Hoiseth , Kathrin Ute Jansen , Justin Keith Moran , Mark Edward Ruppen
IPC: C07K14/22 , A61K39/095
Abstract: In one aspect, the invention relates to a non-lipidated and non-pyruvylated Neisseria meningitidis serogroup B polypeptide and methods of use thereof. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup, and methods of use thereof.
-
3.发明申请公开(公告)号：US20200254081A1
公开(公告)日：2020-08-13
申请号：US16647124
申请日：2018-09-14
Applicant: Pfizer Inc.
Inventor： Kathrin Ute Jansen , Annaliesa Sybil Anderson , Robert G.K. Donald , Michael James Flint , Nicholas Randolph Everard Kitchin , Justin Keith Moran , Louise Pedneault , Michael W. Pride , Mark Edward Ruppen , Christopher Frederick Webber
Abstract: In one aspect, the invention relates to an immunogenic composition that includes a Clostridium difficile toxoid A and/or a C. difficile toxoid B, and methods of use thereof. In another aspect, the invention relates to a method for eliciting an immune response in a human against a C. difficile infection. The method includes administering to the human an effective dose of a composition, which includes a C. difficile toxoid, wherein the composition is administered at least two times, wherein the second administration is about 30 days after the first administration, and wherein the immune response against C. difficile toxin A and/or toxin B is sustained.
-
公开(公告)号：US20190127426A1
公开(公告)日：2019-05-02
申请号：US16208347
申请日：2018-12-03
Applicant: PFIZER INC.
Inventor： Annaliesa Sybil Anderson , Susan Kay Hoiseth , Kathrin Ute Jansen , Justin Keith Moran , Mark E. Ruppen
IPC: C07K14/22 , A61K39/095
CPC classification number: C07K14/22 , A61K39/095 , A61K2039/55505 , A61K2039/58 , A61K2039/6037 , A61K2039/70
Abstract: In one aspect, the invention relates to a non-lipidated and non-pyruvylated Neisseria meningitidis serogroup B polypeptide and methods of use thereof. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup, and methods of use thereof.
-
公开(公告)号：US08986710B2
公开(公告)日：2015-03-24
申请号：US13787594
申请日：2013-03-06
Applicant: Pfizer Inc.
Inventor： Annaliesa Sybil Anderson , Susan Kay Hoiseth , Kathrin Ute Jansen , Justin Keith Moran , Mark E. Ruppen
IPC: A61K39/095 , C07K14/22 , C07H21/04 , C07K16/12 , A61K39/00
CPC classification number: A61K39/095 , A61K2039/55577 , A61K2039/6018 , C07K14/22 , C07K16/1217
Abstract: In one aspect, the invention relates to an isolated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 71. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup.
Abstract translation: 一方面，本发明涉及包含与SEQ ID NO：71具有至少95％同一性的氨基酸序列的分离多肽。另一方面，本发明涉及免疫原性组合物，其包含分离的非脂化非 - 来自脑膜炎奈瑟氏球菌血清群B的丙酮酸化ORF2086多肽和来自脑膜炎球菌血清群的至少一种共轭荚膜糖。
-
Patent Agency Ranking
公开(公告)号：US20230085173A1
公开(公告)日：2023-03-16
申请号：US17799992
申请日：2021-02-17
Applicant: Pfizer Inc.
Inventor： Ling Chu , Wei Chen , Nishith Merchant , Justin Keith Moran
Abstract: The present invention relates to methods for purifying bacterial polysaccharides, in particular for removing impurities from cellular lysates of bacteria producing polysaccharides, comprising: a) acid hydrolysis; b) a first ultrafiltration/diafiltration-(UFDF-1); b) carbon filtration; c) chromatography; and d) a second ultrafiltration/diafiltration-(UFDF-2).
-
公开(公告)号：US20220168410A1
公开(公告)日：2022-06-02
申请号：US17672126
申请日：2022-02-15
Applicant: Pfizer Inc.
Inventor： Robert G.K. Donald , Annaliesa Sybil Anderson , Laurent Oliver Chorro , Jianxin Gu , Jin-Hwan Kim , Srinivas Kodali , Jason Arnold Lotvin , Justin Keith Moran , Rosalind Pan , Avvari Krishna Prasad , Mark Edward Ruppen , Suddham Singh , Ling Chu , Scott Ellis Lomberk , Karen Kiyoko Takane , Nishith Merchant , Wei Chen
IPC: A61K39/108 , C08B37/00 , A61P31/04 , A61P37/04
Abstract: In one aspect, the invention relates to an immunogenic composition comprising modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof. Multivalent vaccines may be prepared by combining two or more monovalent immunogenic compositions for different E. coli serotypes. In one embodiment, the modified O-polysaccharide molecules are produced by a recombinant bacterium that includes a wzz gene.
-
公开(公告)号：US20200123206A1
公开(公告)日：2020-04-23
申请号：US16713782
申请日：2019-12-13
Applicant: PFIZER INC.
Inventor： Annaliesa Sybil Anderson , Susan Kay Hoiseth , Kathrin Ute Jansen , Justin Keith Moran , Mark Edward Ruppen
IPC: C07K14/22 , A61K39/095
Abstract: In one aspect, the invention relates to a non-lipidated and non-pyruvylated Neisseria meningitidis serogroup B polypeptide and methods of use thereof. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup, and methods of use thereof.
-
公开(公告)号：US20160030543A1
公开(公告)日：2016-02-04
申请号：US14604620
申请日：2015-01-23
Applicant: PFIZER INC.
Inventor： Gary Warren Zlotnick , Susan Kay Hoiseth , Kathrin Ute Jansen , Justin Keith Moran , Mark E. Ruppen , Annaliesa Sybil Anderson , John Erwin Farley , Liesel A. Bernfield
IPC: A61K39/095 , C07K14/22
CPC classification number: A61K39/095 , A61K2039/55577 , A61K2039/6018 , C07K14/22 , C07K16/1217
Abstract: In one aspect, the invention relates to an isolated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 71. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup.
-
公开(公告)号：US20160017006A1
公开(公告)日：2016-01-21
申请号：US14773324
申请日：2014-03-05
Applicant: PFIZER INC.
Inventor： Deborah Ann Dilts , Annaliesa Sybil Anderson , Kathrin Ute Jansen , Justin Keith Moran , Mark E Ruppen , Eugene Joseph Vidunas
IPC: C07K14/22 , A61K39/095 , A61K39/09 , C07K14/315
CPC classification number: C07K14/22 , A61K39/092 , A61K39/095 , A61K2039/6037 , A61K2039/6068 , C07K14/3156 , C07K2319/00 , C07K2319/55
Abstract: In one aspect, the invention relates to an isolated polypeptide including the amino acid sequence of a carrier polypeptide and the amino acid sequence of an ORF2086 polypeptide. In another aspect, the invention relates to an immunogenic conjugate including ORF2086 polypeptide and a carrier polypeptide. The invention further includes immunogenic compositions and methods for inducing an immune response against Neisseria meningitidis in a mammal.
Abstract translation: 一方面，本发明涉及包含载体多肽的氨基酸序列和ORF2086多肽的氨基酸序列的分离的多肽。 另一方面，本发明涉及包含ORF2086多肽和载体多肽的免疫原性缀合物。 本发明还包括用于在哺乳动物中诱导针对脑膜炎奈瑟氏球菌的免疫应答的免疫原性组合物和方法。
-
-
-
-
-
-
-
-
-
Search Results
40
records
(took 0.025 seconds)
